A look back at prolactinoma care in teens and young adults
Original title: Prolactinomas in the transition from adolescence to young adulthood: A multicentre, retrospective study from the TALENT group.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This looked back at care patients already got, not a new treatment.
The short version
Doctors reviewed how 110 young people with a pituitary growth were treated.
What was studied. Doctors looked back at records of 110 patients aged 15 to 25, and 33 were male. They were treated at five centers in Italy between 2010 and 2025.
What they found. Almost all patients, 95%, first took a drug called cabergoline. A hormone called prolactin went back to normal in 75% of them. Tumors got much smaller in 66%, but 40% responded only in part. Of those who stopped the drug after a long normal stretch, 61% saw the problem come back.
What this means, and what it doesn't
What it could mean: Cabergoline helped many young people in this group. But the tumor often came back when the drug was stopped. This is a reason to talk with your doctor before stopping any medicine.
What it doesn't mean: This is not a cure, and it is not a new treatment. The doctors only read old records. They did not run a trial or test anything new. So this cannot prove what caused each result. Your own care may look different. Ask your care team what fits you.
Source: PubMed, October 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.